From bench to bedside: translating novel-target ADCs against treatment-resistant tumors

“...the antibody, the target, the antibody against the target, the linker, and the payload; it all matters.”

Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights , speaks with Valerie Vanhooren, Co-Founder and CEO, Ona Therapeutics, about translating first-in-class ADCs from bench to bedside, including target validation, resistance biology, linker-payload strategy, and the company culture that sustains high-risk, high-gain drug development.

Please enter your email to access content Read now